Sample   Age at     Days of   Sample Gender OLT preCT state CT treatment Diagnosis type follow up     (mths)                     Pt1 T + S F 20 Pretext III, P1 SIOPEL IV 1240 Hepatoblatoma Pt2† T M 23 Pretext III, P1 SIOPEL IV 2 Hepatoblatoma Pt3 T + S F 31 Pretext IV, SIOPEL IV 1410 Hepatoblatoma V1               Pt4† T F 37 Pretext III SIOPEL III 150 Hepatoblatoma Pt5° T M 15* Pretext II SIOPEL III 2160 Hepatoblatoma Pt6° T M 143* Pretext II SIOPEL III lost Hepatoblatoma Pt7 T + S F 8 Pretext III, P1 SIOPEL IV 1021 Hepatoblatoma V2               Pt8° S M 17* Pretext II SIOPEL IV 345 Hepatoblatoma Pt9 S F 34 Pretext IV SIOPEL III 2550 Hepatoblatoma Pt10 S M 30 Pretext IV, SIOPEL III 2023 Hepatoblatoma P1, V2               Pt11 S M 14 Pretext IV SIOPEL IV 471 Hepatoblatoma Pt12 S M 63 Pretext IV SIOPEL II 4747 Hepatoblatoma Pt13 S F 32 Pretext IV SIOPEL IV 1266 Hepatoblatoma Pt14 S M 8 Pretext III SIOPEL III 1873 Hepatoblatoma Ctr1§ T M/F 20-38 NA NA NA Normal pooled weeks human fetal livers             Ctr2 § T M 288- NA NA NA Normal pooled 768 livers                           non-neoplastic part Ctr3† T F 37 Pretext III SIOPEL III 150 of a liver explanted               for HB Ctr4 S M 37 NA NA 559 Familial cholestasis Ctr5 S M 8 NA NA 849 Biliary atresia Ctr6 S M 192 NA NA 1415 Sclerosing cholangitis               Ctr7 S F 95 NA NA 3292 Vascular anomaly Ctr8 S F 5 NA NA 3281 Biliary atresia Ctr9 S F 73 NA NA 1273 Familial cholestasis Ctr10 S F 96 NA NA 1101 Sclerosing cholangitis               Ctr11 S M 49 NA NA 842 Urea cycle disorder Ctr12 S M 12 NA NA 6734 Biliary atresia Ctr13 S F 13 NA NA 7307 Biliary atresia Ctr14 S F 18 NA NA NA Healthy donors Ctr15 S M 13 NA NA NA Healthy donors Ctr16 S M 25 NA NA NA Healthy donors Ctr17 S F 22 NA NA NA Healthy donors

S Serum T Tissue OLT Orthotopic Liver Transplantation CT Chemotherapy * Age at SLR (Surgical Liver Resection) NA Not applicable § Commercial RNA (Clonetech) † Dead patient - Not available ° hepatic resection

Table 1: Clinical features of HB patients (Pt, N=14) and Controls (Ctr, N=17) enrolled in the study